An early combination of concurrent chemoradiotherapy with immune checkpoint inhibitors for cervical cancer is superior to a late combination: a propensity-score matching analysis

An early combination of concurrent chemoradiotherapy with immune checkpoint inhibitors for cervical cancer is superior to a late combination: a propensity-score matching analysis

PurposeThis study compared the timing effects of immune checkpoint inhibitor (ICIs) administration on the efficacy and safety of concurrent chemoradiotherapy for cervical cancer.MethodsThis study included patients with advanced cervical cancer who received concurrent chemoradiotherapy with ICIs. The...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yi-Ming Ma, Shu-Xia Cheng, Ming-Chuan Zhang, Hui-Ying Zhang, Jun-Jiao Gu, Pan-Pan Zhao, Hong Ge
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Oncology
Subjects:	immune checkpoint inhibitors cervical cancer application timing progression-free survival objective response rate treatment-related adverse events
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1429176/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis
by: Zhihong Zhao, et al.
Published: (2024-09-01)

Corrigendum: Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis
by: Zhihong Zhao, et al.
Published: (2024-11-01)

Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials
by: Xinmiao Zhang, et al.
Published: (2024-12-01)

Longitudinal dynamic MRI radiomic models for early prediction of prognosis in locally advanced cervical cancer treated with concurrent chemoradiotherapy
by: Chang Cai, et al.
Published: (2024-12-01)

Early Alpha-Fetoprotein Response Predicts Sustained Tumor Response Following Immune Checkpoint Inhibitors Combined with Targeted Therapy in Liver Cancer
by: Jiahe Tian, et al.
Published: (2024-12-01)

Comprehensive Evaluation of Inflammatory Biomarkers in Cervical Cancer Treated with Chemoradiotherapy
by: Timur Koca, et al.
Published: (2025-01-01)

Pilot study of combined FDG‐PET and dynamic contrast‐enhanced CT of locally advanced cervical carcinoma before and during concurrent chemoradiotherapy suggests association between changes in tumor blood volume and treatment response
by: Thomas I. Banks, et al.
Published: (2018-08-01)

Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study
by: Sho Kiyota, et al.
Published: (2024-10-01)

Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis
by: Yichen Zheng, et al.
Published: (2024-12-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

Analysis of the implementation value of abdominal B-ultrasound combined with cervical cerclage in the prevention and treatment of late recurrent spontaneous abortion
by: Lili Shi, et al.
Published: (2024-12-01)

A comparative analysis of toxicity and treatment outcomes of adaptive radiotherapy and intensity-modulated radiotherapy in cervical cancer
by: Xiaohan Liu, et al.
Published: (2025-01-01)

Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
by: Liu Song, et al.
Published: (2025-01-01)

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer
by: Xue Zhang, et al.
Published: (2024-12-01)

Surgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching
by: Takao Shigenobu, et al.
Published: (2025-01-01)

MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer
by: Kari S. Wagner-Larsen, et al.
Published: (2025-01-01)

Long-Term Outcomes of Modified Expansive Open-Door Laminoplasty Combined with Short-Level Anterior Cervical Fusion in Multilevel Cervical Spondylotic Myelopathy
by: Szu-Wei Chen, et al.
Published: (2024-12-01)

Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
by: Pengyuan Liu, et al.
Published: (2023-02-01)

Cervical length of preoperative cervical cerclage prognostic impacted the effect of cervical insufficiency
by: Yayun Zhang, et al.
Published: (2025-01-01)

Overexpression of C1orf74 predicts poor outcome and promote cervical cancer progression
by: Hai Zhu, et al.
Published: (2024-12-01)

A Clinical Prediction Model for Pathologic Upgrade to Invasive Carcinoma Following Conization of Cervical High‐Grade Squamous Intraepithelial Lesions
by: Qiao Liu, et al.
Published: (2025-01-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Complete remission after sintilimab combined with chemoradiotherapy in double primary head and neck carcinoma: case report
by: Xiameng Lu, et al.
Published: (2024-12-01)

Risk Factors of Catheter-Associated Urinary Tract Infections Following Radical Hysterectomy for Cervical Cancer: A Propensity Score Matching-Based Study
by: Zhou M, et al.
Published: (2024-12-01)

Mir-615-5p inhibits cervical cancer progression by targeting TMIGD2
by: Yan Zhao, et al.
Published: (2025-01-01)

Prediction of outcomes after chemoradiotherapy for cervical cancer by neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
by: Jing Yu, et al.
Published: (2024-12-01)

Addition of PARP1-inhibition enhances chemoradiotherapy and thermoradiotherapy when treating cervical cancer in an in vivo mouse model
by: Marloes IJff, et al.
Published: (2025-12-01)

Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles
by: Yuxuan Liu, et al.
Published: (2024-11-01)

Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors
by: Zhou Y, et al.
Published: (2024-12-01)

Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
by: Zhenyun Yang, et al.
Published: (2024-12-01)

Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice
by: Jun Gu, et al.
Published: (2024-12-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition
by: Yasmin F Melzer, et al.
Published: (2025-02-01)

Cervical Pap smear is gold diagnostic tool for cervical cancer
by: Manal Abd Ali, et al.
Published: (2013-06-01)

Pregnancy outcomes of twin pregnancies with cervical insufficiency undergoing cervical cerclage
by: Jiahao Zhu, et al.
Published: (2024-11-01)

Role of spindle assembly checkpoint proteins in gametogenesis and embryogenesis
by: Renju Pun, et al.
Published: (2025-01-01)

The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Lei Liu, et al.
Published: (2025-01-01)

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
by: Jing Wei, et al.
Published: (2024-12-01)

Cervical cerclage vs cervical pessary in women with cervical insufficiency: A multicentric, open-label, randomised, controlled pilot trial [the CEPEIC trial]
by: Andrea Gascón, et al.
Published: (2024-12-01)

Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis
by: Shengfa Lin, et al.
Published: (2024-12-01)